September 2018 FDA Recall Clozapine by Teva Pharmaceuticals Usa
D-0001-2019 - Failed Disintegration Specifications

This Class II drug recall was voluntarily initiated by Teva Pharmaceuticals Usa on September 21, 2018 for the product Clozapine. The FDA reported the reason for recall as failed disintegration specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0001-2019

Reason for Recall
Failed Disintegration Specifications: Out-of-specification disintegration test result obtained during routine stability testing.
Initiated
09-21-2018
Reported
10-10-2018
Quantity
313 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Teva Pharmaceuticals USA
Distributed nationwide in the USA
Clozapine Orally Disintegrating Tablets, 12.5 mg, 100-count bottles, Rx only, Teva Pharmaceuticals USA, Inc., North Wales, PA 19454, NDC 0093-5416-01 Yellow, round, flat-faced, beveled-edge, unscored tablet. Debossed with 13 on one side and plain on the other side.

Batch or Lot Expiration Information

Lot# : 34034024B, Exp 02/20